You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Select search scope: search across all journals or within the current journal

Search this journal

Enter search terms…

Advanced search

Browse

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

All content on this site: Copyright © 2026 Sage Publications. All rights reserved. This website is technically supported and operated by China National Publications Import and Export (Group) Co., Ltd. 京ICP备09090397号-11

High discontinuation rate of natalizumab in JC virus seropositive patients due to significant anxiety and safety feelings

Multiple Sclerosis Journal

Impact Factor: 5.0 / 5-Year Impact Factor: 5.2

Journal Homepage Submission guidelines

Restricted access

Letter

First published online October, 2014

High discontinuation rate of natalizumab in JC virus seropositive patients due to significant anxiety and safety feelings

Volume 20, Issue 12

https://doi.org/10.1177/1352458514526945

Abstract

Get full access to this article

View all access options for this article.

References

van Rossum

Vennegoor

Balk

. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients. Mult Scler 2014; 20:108–111.

Rinaldi

Seppi

Calabrese

. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012; 18: 1640–1643.

Browse journal

Current issue OnlineFirst All issues

Similar articles

Retricted access

Advanced MRI measures like DTI or fMRI should be outcome measures in future clinical trials – NO

Retricted access

Clinical course of multiple sclerosis: A nationwide cohort study

Retricted access

A Parallel-Group Comparison of Budesonide and Beclomethasone Dipropionate for the Treatment of Perennial Allergic Rhinitis in Adults

Retricted access

Methylprednisolone treatment in multiple sclerosis: effect of treatment,pharmacokinetics,future